Background on adjuvant therapy for breast cancer

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 3 SUPPL. 7, 2006, Pages 4-5

  Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE; EVIDENCE BASED MEDICINE; HUMAN; LEUKOCYTE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PATIENT SELECTION; RECURRENCE RISK; RECURRENT CANCER; RISK REDUCTION; SIDE EFFECT; THROMBOCYTE;

EID: 35848940050     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Bonadonna G, Moliterni A, Zambetti M. et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohorr study. BMJ 2005;330:217.
2. Jones SE, Salmon SE, Allen H, et Al. Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy. interim results of an ongoing clinical trial. Recent Results Cancer Res. 1982:80:162-169.
3. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinducdon therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483-1496.
4. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988;6:1611-1620.
5. Slamon DJ, Leyland-Jones B, Shak S, et -al. Use ofchemodierapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.